Stryker shares seen offering valuation upside after cyberattack setback

Traders Union
All News
Stocks
Stryker shares valuation upside

Highlights

Stryker shares trade near $304, about 23% below the 52-week high of $392.55, presenting potential valuation upside following temporary cyberattack and supply disruptions.
Stryker reported organic revenue growth of about 10% annually and adjusted earnings per share growth of 12% to 13% per year over the past five years.
Leadership transition announced with Spencer Stiles to succeed CEO Kevin Lobo in 2025, with sustainable margins around 26% and continued high-end sales growth targeted through 2028.

Leadership change and recent pressures

As reported by CNBC, Sarat Sethi says Stryker remains a top pick for his firm and views the recent weakness in the stock as a buying opportunity despite a cyberattack earlier this year and supply disruption at its Inari business that affected second-quarter 2026 growth.

Stryker, based in Portage, Michigan, makes medical devices and equipment used in surgery, including orthopedic implants, instruments and robotic systems. The company generates more than $25 billion in annual revenue and serves more than 150 million patients, while management has also outlined a leadership transition after announcing on Oct. 6 that Spencer Stiles will succeed CEO Kevin Lobo next year, with Lobo becoming executive chairman.

Sethi says those setbacks are temporary and sees Stiles, a 27-year veteran of the company, as well positioned to extend Stryker’s operating track record. The main risks he identifies are longer-lasting operational disruption and potential changes to government healthcare funding that could reduce procedure volumes and profitability.

Competitive position and growth outlook

Stryker holds leading positions across much of its portfolio and is organized into 22 specialized businesses, a structure that allows each unit to focus on its market while still benefiting from the scale of a global medical technology company. The business has also completed about 60 acquisitions over the past decade, strengthening its relationships with hospitals and widening a product range that Sethi says is difficult for rivals to replicate.

Over the past five years, Stryker has grown organic revenue by about 10% annually, around 4 percentage points faster than the markets it serves, while adjusted earnings per share have risen about 12% to 13% a year. Adjusted operating margins reached about 26% last year, and the company is targeting sales growth at the high end of the medical technology industry through 2028, supported by new products and expansion into faster-growing businesses.

Sethi also highlights Stryker’s Mako robotic system as a key growth driver as hospitals seek greater surgical precision and more facilities adopt robotic-assisted procedures. He says an aging population and the shift of surgeries from hospitals to outpatient centers should further support demand, while the stock’s level near $304 a share, roughly 23% below its 52-week high of $392.55, leaves room for the valuation to recover toward its historical forward earnings range of 24 to 25 times if operations stabilize.

In our earlier coverage of CTOS Digital’s cybersecurity incident, we detailed how the breach was expected to pressure the company’s results through service disruptions and higher recovery costs. We noted management’s estimate that profit after tax could fall by RM12 million and revenue by RM16 million if some services stayed affected into late October, with further downside risk for every additional week of disruption.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.